NCT02447419 2022-06-15
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
Samsung Medical Center
Phase 2 Completed
Clinical Trials
8 trialsNCT00186979 2017-04-26
Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00084708 2014-01-13
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00039390 2013-01-25
Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00040781 2013-01-23
Gefitinib in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00025207 2013-01-17
Gefitinib in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00084786 2013-01-17
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00787410 2012-06-06
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
AstraZeneca
Phase 2 Completed